Publication

EHA •
14 June, 2024 •
•

A Phase 3, Randomised, Double-Blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia (AVA-PED-301)

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Jessica Zhang, Linda Smallwood, Emily de León, Brian D. Jamieson

Available materials

Oral Presentation

Publication

EHA •
14 June, 2024 •
•

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

Srikanth Nagalla, My Levy, Shruti Chaturvedi, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg , Scott Kolodny

Publication

EHA •
14 June, 2024 •
•

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Francesco Zaja, Quentin Hill, Fiona Glen, Fatemeh Saberi Hosnijeh, Luca Le Treust, Lara Groves, Milica Putnik, Carly Rich

Publication

EHA •
14 June, 2024 •
•

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

Srikanth Nagalla, Cecilie Yssing, Donatella Decise, Milica Putnik, Carly Rich

Publication

Efficacy and safety of intensive pegcetacoplan dosing for the treatment of acute hemolysis in patients with paroxysmal nocturnal hemoglobinuria

A Phase 3, Randomised, Double-Blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Paediatric Subjects with Immune Thrombocytopenia (AVA-PED-301)

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: REAL-AVA 2.0 Interim Analysis Results

A European retrospective study to describe real-world outcomes, treatment patterns and resource use in primary idiopathic thrombocytopenic purpura patients treated with avatrombopag: Interim results

Impact of thrombopoietin receptor agonists and adherence to instructions for treatment of chronic primary immune thrombocytopenia: interim results of a real-world cross-sectional international survey

One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults

Analysis of Baseline Influences on Platelet Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Pati

Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure

Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration